🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Glad to attend the 3rd Chris Wood GU Onc meeting! We remember our friend and board chair Dr Wood so fondly. So many friends and advocates working to advance science and improve lives in his memory - thank you! #kidneycancer #guoncology #advocacy

We partnered with @sickcells for the April Priority Topic Meeting: Sickle Cell Trait, Fitness & Kidney Health feat. Daniel Shapiro. Webinar open to Sick Cells Ambassadors, join bit.ly/3jL6CzA Read Salvatore La Rosa's blog with more research details! bit.ly/3rGc40n

Kidney Cancer partnered with Sick Cells for the April Priority Topic Meeting Kidney Cancer @sickcells Daniel Shapiro Salvatore La Rosa oncodaily.com/blog/kidney-ca… #KidneyCancer #SickCells #Cancer #OncoDaily #Medicine #Oncology #MedEd #MedX #MedNews

You want to hear the truth, and only the truth? You just tune in to KaelinLab again: amjmed.com/article/S0002-…

Our UW Urologic Oncology suo fellow Paz lotan kicking off with his first of 11 accepted abstracts! Great to see his hard work paying off. #AUA25 Society of Urologic Oncology

Nice presentation by Parth Shah ⁦Daniel Shapiro⁩ ⁦UW Urology⁩ ⁦UW Urologic Oncology⁩ ⁦Viraj Master⁩ ⁦Chas Peyton⁩ ⁦Sarah P. Psutka MD MS⁩ ⁦Philippe spiess⁩

Drs Shapiro and Karam with multicenter study on preop eval for sarc RCC ⁦Daniel Shapiro⁩ ⁦Arighno Das⁩ ⁦Philippe spiess⁩ ⁦Chas Peyton⁩ ⁦Sarah P. Psutka MD MS⁩ ⁦Jay Raman⁩ ⁦Chiara Mercinelli⁩ ⁦Andrea Necchi⁩ ⁦Surena F Matin MD⁩ ⁦Viraj Master⁩

Higher levels of arsenic found in dust in homes of patients with bladder cancer! Arighno Das UW Urology UW Urologic Oncology #AUA25

Great job pgy5 Ali Ghasemzadeh, MD, PhD on your poster #AUA25! UW Urologic Oncology Society of Urologic Oncology E Jason Abel

UW Madison Urology Residency Resident Abstract Olympic Medalists for 2025! So proud of our Residents! #AUA25 UW Urology Amer. Urol. Assn. Dave Penson

Outstanding work by Paz lotan improving our ability to detect pt3 disease on preop imaging to improve periop therapy trial enrollment #AUA2025 UW Urologic Oncology UW Urology Society of Urologic Oncology Kidney Cancer

Pleasure chatting about this less mainstream treatment strategy and our promising trial and biomarker results. Pavlos Msaouel

Excellent study on recurrence in high risk RCC by ⁦Daniel Shapiro⁩ ⁦Viraj Master⁩ ⁦Kyle A. Richards⁩ ⁦DJarrard⁩

Photo op with the famous Dan Williams, Program Director, and urologist extraordinaire. He proudly wears our medal from the Resident Abstract Olympics! Great work by residents, faculty and fellows! Amer. Urol. Assn. UW Urology #AUA25

His final presentation looking at barriers to genetic counseling in RCC. Congrats Paz lotan on an outstanding job at #AUA2025. UW Urologic Oncology UW Urology E Jason Abel Steve Nakada

1/5 People living with sickle-cell disease (SCD) face ↑ cancer risk, including #RenalMedullaryCarcinoma. Our latest Immunity study suggests a culprit is the reshaping CD8⁺ T cell chromatin by SCD 👉authors.elsevier.com/sd/article/S10… #MsaouelLab

Appreciate Significance making the primer on randomized non-comparative trials (RNCTs) freely available help to raise awareness of this phenomenon: academic.oup.com/jrssig/article… Frank Harrell Miguel Hernán Richard Riley (R²) Sander Greenland Andrew Vickers Ethan Ludmir MD Alexander Sherry

Daniel D. Shapiro, MD, FACS, (Daniel Shapiro) and E. Jason Abel, MD, FACS, (E Jason Abel) discuss optimal patient selection for cytoreductive nephrectomy in 2025. UW Urology urologytimes.com/view/patient-s…

In Ep. 13, E Jason Abel, Dr. Louis Hinshaw, and Ruchika Talwar explain how urologists and radiologists work together to improve #kidneycancer treatment. #ONC13 UW Radiology UW Urology UW Urologic Oncology Vanderbilt Urology BackTable Vascular and Interventional ASCO open.spotify.com/episode/3GRagx…

🌟🎓👏🧵 RCC Highlights @ #ASCO25 | Part 1 💬 Brilliant discussion by Tian Zhang, MD, MHS on 4 pivotal studies in advanced ccRCC OncoAlert 🔹 #Abstract4505 | CheckMate 214 – NIVO+IPI vs SUN (Marc Motzer et al) ✔️ 9-year follow-up ✔️ OS benefit in all IMDC groups ✔️ 108-mo OS: 31% vs 20%